PriceTargets.com logo

Syneos Health - SYNH Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $43.00
  • Forecasted Upside: 0.05%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$42.98 As of 09/28/2023 09:00 PM ET
▲ +0.01 (0.02%)
Get New Syneos Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SYNH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYNH

Analyst Price Target is $43.00
▲ +0.05% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Syneos Health in the last 3 months. The average price target is $43.00, with a high forecast of $43.00 and a low forecast of $43.00. The average price target represents a 0.05% upside from the last price of $42.98.

This chart shows the closing price for SYNH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 investment analysts is to hold stock in Syneos Health. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2023MizuhoBoost Target$38.00 ➝ $43.00Low
5/11/2023Robert W. BairdDowngradeOutperform ➝ NeutralLow
5/11/2023Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldLow
5/10/2023BarclaysUpgradeUnderweight ➝ Equal WeightLow
5/10/2023JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralLow
4/4/2023BarclaysLower TargetUnderweight$45.00 ➝ $37.00Low
3/1/2023BarclaysBoost TargetUnderweight$30.00 ➝ $45.00Low
2/17/2023MizuhoReiterated RatingNeutral$38.00Low
2/17/2023Robert W. BairdBoost TargetOutperform$42.00 ➝ $51.00Low
2/13/2023JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$30.00 ➝ $28.00Low
1/13/2023BarclaysDowngradeOverweight ➝ Underweight$30.00 ➝ $25.00Low
12/14/2022MizuhoDowngradeBuy ➝ Neutral$66.00 ➝ $38.00N/A
11/9/2022Deutsche Bank AktiengesellschaftLower Target$77.00 ➝ $51.00Low
11/7/2022Robert W. BairdLower TargetOutperform$80.00 ➝ $42.00Low
11/6/2022BarclaysLower TargetOverweight$60.00 ➝ $30.00Low
11/6/2022CitigroupLower TargetNeutral$55.00 ➝ $30.00Low
10/18/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$85.00 ➝ $53.00N/A
10/12/2022Deutsche Bank AktiengesellschaftLower TargetBuy$99.00 ➝ $77.00Low
10/12/2022MizuhoLower TargetBuy$87.00 ➝ $66.00Low
10/6/2022BarclaysLower TargetOverweight$70.00 ➝ $60.00Low
10/5/2022CitigroupLower TargetNeutral$70.00 ➝ $55.00Low
9/16/2022Robert W. BairdLower TargetOutperform$89.00 ➝ $80.00Low
9/14/2022GuggenheimDowngradeBuy ➝ NeutralLow
9/12/2022BarclaysLower TargetOverweight$80.00 ➝ $70.00Low
9/7/2022UBS GroupInitiated CoverageNeutral$68.00Low
8/9/2022Evercore ISILower Target$73.00Low
8/9/2022Robert W. BairdLower Target$89.00Low
8/3/2022MizuhoLower TargetBuy$94.00 ➝ $87.00N/A
8/3/2022BarclaysLower Target$90.00 ➝ $80.00Low
8/3/2022Robert W. BairdLower Target$99.00 ➝ $89.00Low
8/3/2022CitigroupLower Target$80.00 ➝ $70.00Low
8/3/2022William BlairDowngradeOutperform ➝ Market PerformLow
7/13/2022BarclaysLower TargetOverweight$95.00 ➝ $90.00N/A
5/23/2022GuggenheimInitiated CoverageBuy$81.00Medium
5/20/2022MizuhoReiterated RatingBuy$94.00Low
4/25/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$101.00 ➝ $75.00High
4/11/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$102.00Medium
3/7/2022MizuhoLower TargetBuy$109.00 ➝ $94.00High
1/27/2022BarclaysLower TargetOverweight$115.00 ➝ $105.00Low
12/15/2021CitigroupDowngradeBuy ➝ Neutral$115.00 ➝ $105.00High
11/4/2021Robert W. BairdBoost TargetPositive ➝ Outperform$115.00 ➝ $122.00High
11/4/2021BarclaysUpgradeEqual Weight ➝ Overweight$98.00 ➝ $115.00High
11/4/2021KeyCorpBoost TargetOverweight$100.00 ➝ $105.00High
8/5/2021Credit Suisse GroupBoost TargetOutperform$96.00 ➝ $100.00High
7/13/2021BarclaysBoost TargetEqual Weight$90.00 ➝ $102.00Low
4/30/2021MizuhoBoost TargetBuy$82.00 ➝ $90.00Medium
3/8/2021BarclaysInitiated CoverageEqual Weight$84.00N/A
3/8/2021KeyCorpBoost TargetOverweight$76.00 ➝ $90.00Medium
3/2/2021BarclaysInitiated CoverageEqual Weight$84.00Medium
2/22/2021MizuhoBoost TargetBuy$72.00 ➝ $87.00Medium
2/19/2021CitigroupBoost Target$80.00 ➝ $85.00Low
12/9/2020JPMorgan Chase & Co.Boost TargetOverweight$80.00 ➝ $85.00Low
12/9/2020Smith Barney CitigroupBoost Target$75.00 ➝ $80.00Low
12/9/2020MizuhoBoost TargetPositive ➝ Buy$65.00 ➝ $72.00Low
12/7/2020Credit Suisse GroupBoost TargetOutperform$72.00 ➝ $75.00Medium
10/6/2020MizuhoUpgradeNeutral ➝ Buy$63.00 ➝ $65.00Low
10/1/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$69.00 ➝ $75.00High
8/12/2020Truist FinancialBoost TargetBuy$74.00 ➝ $80.00Medium
8/7/2020CitigroupBoost TargetBuy$70.00 ➝ $75.00Low
8/7/2020MizuhoBoost TargetNeutral$50.00 ➝ $63.00Low
7/16/2020SunTrust BanksBoost TargetBuy$66.00 ➝ $74.00Low
5/1/2020SunTrust BanksBoost TargetBuy$56.00 ➝ $66.00Medium
4/30/2020CfraBoost TargetBuy$55.00 ➝ $61.00Medium
4/28/2020UBS GroupLower TargetNeutral$74.00 ➝ $58.00High
4/9/2020CitigroupLower TargetBuy$85.00 ➝ $65.00High
4/3/2020MizuhoLower TargetNeutral$56.00 ➝ $42.00Medium
4/2/2020Credit Suisse GroupLower TargetOutperform$72.00 ➝ $62.00High
3/30/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$79.00 ➝ $45.00High
3/26/2020BarclaysLower TargetEqual Weight$67.00 ➝ $61.00Medium
3/23/2020Jefferies Financial GroupLower TargetBuy$80.00 ➝ $52.00Medium
3/17/2020SunTrust BanksLower TargetBuy$80.00 ➝ $58.00Low
2/23/2020BarclaysReiterated RatingHold$67.00High
2/21/2020Credit Suisse GroupBoost TargetOutperform$68.00 ➝ $72.00Low
2/21/2020Robert W. BairdBoost TargetOutperform$74.00 ➝ $82.00Low
2/21/2020UBS GroupBoost TargetNeutral$62.00 ➝ $74.00Low
2/21/2020MizuhoBoost TargetNeutral$52.00 ➝ $67.00Low
1/21/2020Credit Suisse GroupReiterated RatingBuy$68.00Low
1/16/2020Robert W. BairdBoost TargetOutperform$62.00 ➝ $74.00Medium
1/16/2020KeyCorpBoost TargetOverweight$65.00 ➝ $71.00Medium
1/6/2020CitigroupInitiated CoverageBuy$75.00Low
9/23/2019Jefferies Financial GroupBoost TargetBuy$62.00 ➝ $65.00Low
9/3/2019KeyCorpBoost TargetOverweight$63.00 ➝ $65.00Low
8/29/2019UBS GroupBoost TargetNeutral$53.50 ➝ $57.00Low
8/23/2019Credit Suisse GroupBoost TargetOutperform$56.00 ➝ $58.00High
8/8/2019KeyCorpBoost TargetOverweight$59.00 ➝ $63.00Low
8/7/2019SunTrust BanksBoost TargetBuy$68.00Low
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/29/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Syneos Health logo
Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina. As of September 28, 2023, Syneos Health, Inc. was taken private.
Read More

Today's Range

Now: $42.98
Low: $42.97
High: $42.99

50 Day Range

MA: $42.86
Low: $42.48
High: $42.98

52 Week Range

Now: $42.98
Low: $22.89
High: $52.23

Volume

7,386,200 shs

Average Volume

1,924,736 shs

Market Capitalization

$4.46 billion

P/E Ratio

62.29

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Syneos Health?

The following equities research analysts have issued reports on Syneos Health in the last year: Barclays PLC, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Mizuho, Robert W. Baird, and StockNews.com.
View the latest analyst ratings for SYNH.

What is the current price target for Syneos Health?

1 Wall Street analysts have set twelve-month price targets for Syneos Health in the last year. Their average twelve-month price target is $43.00, suggesting a possible upside of 0.0%. Mizuho has the highest price target set, predicting SYNH will reach $43.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $43.00 for Syneos Health in the next year.
View the latest price targets for SYNH.

What is the current consensus analyst rating for Syneos Health?

Syneos Health currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SYNH, but not buy more shares or sell existing shares.
View the latest ratings for SYNH.

What other companies compete with Syneos Health?

Other companies that are similar to Syneos Health include Exelixis, National Research, Precigen, PRA Health Sciences and Medpace. Learn More about companies similar to Syneos Health.

How do I contact Syneos Health's investor relations team?

Syneos Health's physical mailing address is 1030 Sync Street, Morrisville NC, 27560. The company's listed phone number is (919) 876-9300 and its investor relations email address is [email protected]. The official website for Syneos Health is www.syneoshealth.com. Learn More about contacing Syneos Health investor relations.